Sellas (Switzerland) is developing an immunotherapeutic cancer vaccine – which can be easier now that the FDA granted it Orphan Drug designations for two types of cancer (for the lung area and a type of leukemia).
Sellas is a biopharma developing treatments for different cancers and diseases of the central nervous system (CNS).
Its lead candidate is the WT1 vaccine has now earned Orphan Drug Designation from the FDA for the treatment of two types of cancer: acute myeloid leukaemia (AML) and malignant pleural mesothelioma (MPM).
This decision follows positive top-line results from phase II trials for both indications.
Regarding AML, Sellas’ trial enrolled 22 patients, whose average overall survival was more than 4 years. For MPM, the double-blind trial found a 21-month increase in the overall survival rate of treated patients.
Sellas expects to advance with phase III trials for both cancers in 2016. The Orphan Drug Designation can certainly help with this process,